Business
Phoenix Asia Holdings Limited Announces Entering into Stock Acquisition Agreement and Convertible Promissory Note
Hong Kong, May 04, 2026 (GLOBE NEWSWIRE) -- Phoenix Asia Holdings Limited (the “Company” or “Phoenix Asia”) (NASDAQ: PHOE), a Hong Kong-based company mainly engaged in substructure works, announces a significant update in its business development. Phoenix Asia is pleased to announce entering into a stock acquisition agreement (the “Stock Acquisition Agreement”) with ACEA Pharma, Inc., an exempted company incorporated with limited liability in the Cayman Islands (“Target Company”) and ACEA Therap
About this update from Phoenix Asia Holdings Limited
[{"type":"image","alt":"Phoenix Asia Holdings Limited","displaySize":"","headline":null,"caption":"Phoenix Asia Holdings Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":114,"height":43,"url":"https://media.zenfs.com/en/globenewswire.com/fbbcaae91168b7401f6626b82cc26152"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XT9nDowAI7u3_Xnt5o9pvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTc5/https://media.zenfs.com/en/globenewswire.com/fbbcaae91168b7401f6626b82cc26152","width":114,"height":43}},"lazy":false},{"type":"text","content":"Hong Kong, May 04, 2026 (GLOBE NEWSWIRE) -- Phoenix Asia Holdings Limited (the “Company” or “Phoenix Asia”) (NASDAQ: PHOE), a Hong Kong-based company mainly engaged in substructure works, announces a significant update in its business development.","length":247,"tagName":"p"},{"type":"text","content":"Phoenix Asia is pleased to announce entering into a stock acquisition agreement (the “Stock Acquisition Agreement”) with ACEA Pharma, Inc., an exempted company incorporated with limited liability in the Cayman Islands (“Target Company”) and ACEA Therapeutics, Inc., an exempted company incorporated with limited liability in the Cayman Islands (the “Transferor”) for the acquisition of 100% of the issued and outstanding shares of common stock of Target Company (the “Company Shares”). The Target Company is a clinical stage pharmaceutical company with a diverse product portfolio to address unmet medical needs in cancer, autoimmune disease, and Covid-19.","length":656,"tagName":"p"},{"type":"text","content":"The Company is also pleased to announce entering into a convertible promissory note with a principal sum of $20,000,000.00 (the “Note”) with Phoenix Prosperity Investment Limited, the controlling stockholder of the Company (the “Holder”).","length":238,"tagName":"p"},{"type":"text","content":"About the Stock Acquisition Agreement","length":37,"tagName":"p"},{"type":"text","content":"On May 4, 2026, the Company entered into the Stock Acquisition Agreement with (i) the Target Company; and (ii) the Transferor. The Transferor holds 100% of the issued and outstanding equity interests of Target Company. Pursuant to the Stock Acquisition Agreement, at the Closing (as defined in the Stock Acquisition Agreement), the Company shall acquire all the issued and outstanding equity interests of the Target Company from the ...